Healthcare Active Movers; Pfizer Inc. (NYSE:PFE), Novavax (NASDAQ:NVAX), Arena Pharmaceuticals (NASDAQ:ARNA), MannKind Corporation (NASDAQ:MNKD)



Pfizer Inc (NYSE:PFE) was the target of a large growth in short interest in the month of May. As of May 15th, there was short interest totalling 59,856,772 shares, a growth of 14.0% from the April 30th total of 52,494,773 shares, StockRatingsNetwork.com reports. Currently, 0.9% of the shares of the company are sold short. Pfizer Inc. (NYSE:PFE) stock performance was -1.14% in last session and finished the day at $29.42. Traded volume was 26.82million shares in the last session and the average volume of the stock remained 30.38million shares. The beta of the stock remained 0.67. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Analysts at Ladenburg Thalmann raised their price target on shares of Novavax Inc. (NASDAQ:NVAX) from $4.00 to $10.00 in a research note on Tuesday, March 11th. They now have a “buy” rating on the stock. Seven research analysts have rated the stock with a buy rating, Novavax has an average rating of “Buy” and an average target price of $10.70. Novavax, Inc. (NASDAQ:NVAX) dropped -7.85 percent to $4.16 Friday on volume of 23.86million shares. The intra-day range of the stock was $4.09 to $4.26. Novavax, Inc. (NASDAQ:NVAX) has a market capitalization of $871.63million.

Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) on June 3 announced the initiation of dosing in an investigational Phase 1b clinical trial of APD334, a novel, oral drug candidate that targets the sphingosine 1-phosphate subtype 1 (S1P1) receptor, to evaluate the compound for the treatment of a number of autoimmune diseases. This randomized, double-blind and placebo-controlled Phase 1b trial will evaluate the safety, tolerability and pharmacokinetics of multiple-ascending doses of APD334 in up to 96 healthy adult volunteers. Arena Pharmaceuticals, Inc. (NASDAQ:ARNA)’s stock on June 06, 2014 reported a decrease of -2.44% to the closing price of $6.00. Its fifty two weeks range is $4.05 -$9.05. The total market capitalization recorded $1.32billion. The overall volume in the last trading session was 10.55million shares. In its share capital, ARNA has 219.65million outstanding shares.

MannKind Corporation (NASDAQ:MNKD) VP David Thomson sold 133,000 shares of the company stock on the open market in a transaction dated Wednesday, June 4th. The stock was sold at an average price of $9.95, for a total value of $1,323,350.00. Following the sale, the vice president now directly owns 102,286 shares of the company’s stock, valued at approximately $1,017,746.On Friday, shares of MannKind Corporation (NASDAQ:MNKD) advanced 2.39% to close the day at $10.28. Company monthly performance is recorded as 65.81%. MannKind Corporation (NASDAQ:MNKD) quarterly revenue growth is 80.04%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone